Journal of Contemporary Brachytherapy
eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Share:
Send email
Share:
Original paper

Percutaneous coronary intervention followed by intravascular brachytherapy for management of drug-eluting stents in-stent restenosis in patients with complex coronary artery lesions

Mark Trombetta
1, 2
,
Hirsch Matani
1
,
Hardik A. Valand
3
,
Siddharth B. Reddy
4
,
Triston B. Smith
5
,
Daniel Pavord
1
,
David Lasorda
2, 3

  1. Division of Radiation Oncology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
  2. Drexel University College of Medicine, Pittsburgh Campus, Pittsburgh, PA 15212, USA
  3. Division of Interventional Cardiology, Allegheny General Hospital, Pittsburgh, PA 15212, USA
  4. Baptist Memorial Hospital, Columbus, MS 39705, USA
  5. Division of Cardiology, Trinity Health System, Steubenville, OH 43952, USA
DOI: https://doi.org/10.5114/jcb.2025.158502
Online publish date: 2025/12/31
Article file
- Percutaneous coronary intervention.pdf  [0.21 MB]
Get citation
 
 
1. Hozumi T, Yoshikawa J (Eds.). Coronary artery disease in 3-D echocardiography. CRC Press, USA 2007; 1-16.
2. Tsao CW, Aday AW, Almarzooq ZI et al. Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation 2022; 145: E153-E639.
3. MacNeill BD, Jang IK, Wong P. Coronary stents in clinical, interventional and investigational thrombocardiology. Becker R, Harrington R (Eds.). CRC Press (3rd Ed), USA 2022; 453-472.
4. Brown JC, Gerhardt TE, Kwon E. Risk factors for coronary artery disease. In: StatPearls Publishing, StatPearls, USA. https://pubmed.ncbi.nlm.nih.gov/32119297/
5. Dhruva SS, Parzynski CS, Gamble GM et al. Attribution of adverse events following coronary stent placement identified using administrative claims data. J Am Heart Assoc 2020; 9: e013606.
6. Taniwaki M, Stefanini GG, Silber S et al. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J Am Coll Cardiol 2014; 63: 1617-1625.
7. Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
8. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.
9. Serruys PW, Van Hout B, Bonnier H et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 1998; 352: 673-681.
10. Post MJ, Borst C, Kuntz RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. Circulation 1994; 89: 2816-2821.
11. Mintz GS, Popma JJ, Hong MK et al. Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis. Am J Cardiol 1996; 78: 18-22.
12. Rebel RE, Aude MH, Öpp HW et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. N Engl J Med 1998; 339: 1672-1678.
13. Leon MB, Teirstein PS, Moses JW et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med 2001; 344: 250-256.
14. Dangas GD, Claessen BE, Caixeta A et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010; 56: 1897-1907.
15. Mehran R, Dangas G, Abizaid AS et al. Angiographic patterns of in-stent restenosis: Classification and implications for long-term outcome. Circulation 1999; 100: 1872-1878.
16. Kuntz RE, Baim DS. Defining coronary restenosis. Newer clinical and angiographic paradigms. Circulation 1993; 88: 1310-1323.
17. Kim SW, Mintz GS, Escolar E et al. An intravascular ultrasound analysis of the mechanisms of restenosis comparing drug-eluting stents with brachytherapy. Am J Cardiol 2006; 97: 1292-1298.
18. Dibra A, Kastrati A, Alfonso F et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials. J Am Coll Cardiol 2007; 49: 616-623.
19. Sethi A, Malhotra G, Singh S et al. Efficacy of various percutaneous interventions for in-stent restenosis: comprehensive network meta-analysis of randomized controlled trials. Circ Cardiovasc Interv 2015; 8: e002778.
20. Buccheri D, Piraino D, Andolina G et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis 2016; 8: E1150.
21. Megaly M, Glogoza M, Xenogiannis I et al. Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. Catheter Cardiovasc Interv 2021; 97: 32-38.
22. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: A new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv 2019; 12: e007023.
23. Kubo S, Kadota K, Otsuru S et al. Optimal treatment of recurrent restenosis lesions after drug-eluting stent implantation for in-stent restenosis lesions. EuroIntervention 2013; 9: 788-796.
24. Yabushita H, Kawamoto H, Fujino Y et al. Clinical outcomes of drug-eluting balloon for in-stent restenosis based on the number of metallic layers. Circ Cardiovasc Interv 2018; 11: e005935.
25. Theodoropoulos K, Mennuni MG, Dangas GD et al. Resistant in-stent restenosis in the drug eluting stent era. Catheter Cardiovasc Interv 2016; 88: 777-785.
26. Siontis GCM, Stefanini GG, Mavridis D et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet 2015; 386: 655-664.
27. Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2019; 40: 87-165.
28. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Circulation 2011; 124: 574-651.
29. Waksman R, Iantorno M. Refractory in-stent restenosis: Improving outcomes by standardizing our approach. Curr Cardiol Rep 2018; 20: 777-785.
30. Waksman R, White RL, Chan RC et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101: 2165-2171.
31. Hansrani M, Overbeck K, Smout J et al. Intravascular brachytherapy: a systematic review of its role in reducing restenosis after endovascular treatment in peripheral arterial disease. Eur J Vasc Endovasc Surg 2002; 24: 377-382.
32. Cutlip DE, Chauhan MS, Baim DS et al. Clinical restenosis after coronary stenting: Perspectives from multicenter clinical trials. J Am Coll Cardiol 2002; 40: 2082-2089.
33. Varghese MJ, Bhatheja S, Baber U et al. Intravascular brachytherapy for the management of repeated multimetal-layered drug-eluting coronary stent restenosis. Circ Cardiovasc Interv 2018; 11: e006832.
34. Negi SI, Torguson R, Gai J et al. Intracoronary brachytherapy for recurrent drug-eluting stent failure. JACC Cardiovasc Interv 2016; 9: 1259-1265.
35. Nath R, Roberts KB. Vascular irradiation for the prevention of restenosis after angioplasty: A new application for radiotherapy. Int J Radiat Oncol Biol Phys 1996; 36: 977-979.
36. Lobato EB. Care of the patient with coronary stents undergoing noncardiac surgery in essentials of cardiac anesthesia for noncardiac surgery. Kaplan JA (Ed.), Cronin B, Maus T (Assoc. Eds.). Essentials of cardiac anesthesia for noncardiac surgery. Elsevier, Philadelphia, PA 2019.
37. Kim MS, Dean LS. In-stent restenosis. Cardiovasc Ther 2011; 29: 190-198.
38. Alfonso F, Byrne RA, Rivero F et al. Current treatment of in-stent restenosis. J Am Coll Cardiol 2014; 63: 2659-2673.
39. Bønaa KH, Mannsverk J, Wiseth R et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med 2016; 375: 1242-1252.
40. Zhang BC, Karanasos A, Regar E. OCT demonstrating neoatherosclerosis as part of the continuous process of coronary artery disease. Herz 2015; 40: 845-854.
41. Looser PM, Kim LK, Feldman DN. In-stent restenosis: pathophysiology and treatment. Curr Treat Options Cardiovasc Med 2016; 18: 10.
42. Shlofmitz E, Iantorno M, Waksman R. Restenosis of drug-eluting stents: a new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv 2019; 12: e007023.
43. Nakamura D, Yasumura K, Nakamura H et al. Different neoatherosclerosis patterns in drug-eluting- and bare-metal stent restenosis – optical coherence tomography study. Circ J 2019; 83: 313-319.
44. Waksman R, Rodriguez JC, Robinson KA et al. Effect of intravascular irradiation on cell proliferation, apoptosis, and vascular remodeling after balloon overstretch injury of porcine coronary arteries. Circulation 1997; 96: 1944-1952.
45. Hall EJ. Radiobiology for the radiologist. 8th ed. Wolters Kluwer, The Netherlands.
46. Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-495.
47. Sigwart U, Puel J, Mirkovitch V et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-706.
48. Teirstein PS, Massullo V, Jani S et al. Catheter-based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697-1703.
49. Waksman R, White RL, Chan RC et al. Intracoronary γ-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000; 101: 2165-2171.
50. Waksman R, Cheneau E, Ajani AE et al. Intracoronary radiation therapy improves the clinical and angiographic outcomes of diffuse in-stent restenotic lesions: results of the Washington Radiation for In-Stent Restenosis Trial for Long Lesions (Long WRIST) Studies. Circulation 2003; 107: 1744-1749.
51. Holmes DR, Teirstein P, Satler L et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. JAMA 2006; 295: 1264-1273.
52. Stone GW, Ellis SG, O’Shaughnessy CD et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 2006; 295: 1253-1263.
53. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780.
54. Piccolo R, Stefanini GG, Franzone A et al. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents. Circ Cardiovasc Interv 2015; 8: e002223.
55. Kastrati A, Mehilli J, Von Beckerath N et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 2005; 293: 165-171.
56. Detloff LR, Ho EC, Ellis SG et al. Coronary intravascular brachytherapy for in-stent restenosis: A review of the contemporary literature. Brachytherapy 2022; 21: 692-702.
57. Räber L, Jüni P, Löffel L et al. Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation. J Am Coll Cardiol 2010; 55: 1178-1188.
58. Mangione FM, Jatene T, Badr Eslam R et al. Usefulness of intracoronary brachytherapy for patients with resistant drug-eluting stent restenosis. Am J Cardiol 2017; 120: 369-373.
59. Maluenda G, Ben-Dor I, Gaglia MA et al. Clinical outcomes and treatment after drug-eluting stent failure: the absence of traditional risk factors for in-stent restenosis. Circ Cardiovasc Interv 2012; 5: 12-19.
60. Megaly M, Glogoza M, Xenogiannis I et al. Coronary intravascular brachytherapy for recurrent coronary drug-eluting stent in-stent restenosis: a systematic review and meta-analysis. Cardiovasc Revasc Med 2021; 23: 28-35.
61. Bonello L, Kaneshige K, De Labriolle A et al. Vascular brachytherapy for patients with drug-eluting stent restenosis. J Interv Cardiol 2008; 21: 528-534.
62. Meraj PM, Patel K, Patel A et al. Northwell intracoronary brachytherapy for the treatment of recurrent drug eluting stent in-stent restenosis (NITDI study group). Catheter Cardiovasc Interv 2021; 97: 41-46.
63. Habara S, Mitsudo K, Kadota K et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Interv 2011; 4: 149-154.
64. Rittger H, Waliszewski M, Brachmann J et al. Long-term outcomes after treatment with a paclitaxel-coated balloon versus balloon angioplasty: Insights from the PEPCAD-DES study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter). JACC Cardiovasc Interv 2015; 8: 1695-1700.
65. Rittger H, Brachmann J, Sinha AM et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: The PEPCAD-DES study. J Am Coll Cardiol 2012; 59: 1377-1382.
66. Byrne RA, Neumann FJ, Mehilli J et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. Lancet 2013; 381: 461-467.
67. Kufner S, Cassese S, Valeskini M et al. Long-term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv 2015; 8: 877-884.
68. Giacoppo D, Alvarez-Covarrubias HA, Koch T et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J 2023; 44: 1343-1357.
69. Jensen CJ, Richardt G, Tölg R et al. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. EuroIntervention 2018; 14: 1096-1103.
70. Wong YTA, Kang DY, Lee JB et al. Comparison of drug-eluting stents and drug-coated balloon for the treatment of drug-eluting coronary stent restenosis: A randomized RESTORE trial. Am Heart J 2018; 197: 35-42.
71. Alfonso F, Pérez-Vizcayno MJ, Cárdenas A et al. A prospective randomized trial of drug-eluting balloons versus everolimus-eluting stents in patients with in-stent restenosis of drug-eluting stents: The RIBS IV Randomized Clinical Trial. J Am Coll Cardiol 2015; 66: 23-33.
72. Xu B, Gao R, Wang J et al. A prospective, multicenter, randomized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent restenosis: results from the PEPCAD China ISR trial. JACC Cardiovasc Interv 2014; 7: 204-211.
73. Zhu Y, Liu K, Kong X et al. Comparison of drug-coated balloon angioplasty vs. drug-eluting stent implantation for drug-eluting stent restenosis in the routine clinical practice: A meta-analysis of randomized controlled trials. Front Cardiovasc Med 2021; 8: 766088.
74. Serruys PW, Wijns W, Sianos G et al. Direct stenting versus direct stenting followed by centered beta-radiation with intravascular ultrasound-guided dosimetry and long-term anti-platelet treatment. Results of a randomized trial: Beta-Radiation Investigation with Direct stenting and Galileo in Europe (BRIDGE). J Am Coll Cardiol 2004; 44: 528-537.
75. Sharma R, Kumar P, Prashanth SP et al. Dual antiplatelet therapy in coronary artery disease. Cardiol Ther 2020; 9: 349-361.
Copyright: © 2025 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2026 Termedia Sp. z o.o.
Developed by Bentus.